Table 1.
General characteristics of the participants with Parkinson’s disease (PD).
| Participant | Gender | Age | Time since diagnosis (in years) |
Medication for PD | SMMSE score (out of 30) |
Antidepressant |
|---|---|---|---|---|---|---|
| PD1 | F | 70 | 10 | Selegiline, Pramipexole | 30 | Y |
| PD2 | M | 71 | 5 | C-dopa/L-dopa, Pramipexole, Entacapone | 28 | N |
| PD3 | F | 73 | 5 | C-dopa/L-dopa, Pramipexole | 30 | Y |
| PD4 | M | 75 | 15 | C-dopa/L-dopa | 26 | Y |
| PD5 | F | 80 | 6 | C-dopa/L-dopa, Entacapone, Ropinirole | 29 | Y |
| PD6 | F | 75 | 5 | C-dopa/L-dopa, Bromocriptine | 30 | N |
| PD7 | M | 77 | 4 | C-dopa/L-dopa | 27 | N |
| PD8 | M | 79 | 5 | C-dopa/L-dopa, Entacapone, Ropinirole | 26 | N |
| PD9 | M | 70 | 6 | C-dopa/L-dopa | 30 | N |
| PD10 | F | 70 | 5 | C-dopa/L-dopa, Bromocriptine | 28 | Y |
| PD11 | M | 79 | 5 | C-dopa/L-dopa, Mirapex | 30 | N |
| PD12 | M | 82 | 4 | C-dopa/L-dopa, Amantadine | 30 | N |
| PD13 | M | 74 | 5 | C-dopa/L-dopa, Selegiline, Pramipexole | 29 | N |
| PD14 | M | 62 | 5 | C-dopa/L-dopa, Amantadine | 28 | Y |
| PD15 | M | 67 | 12 | C-dopa/L-dopa | 30 | Y |
| PD16 | M | 71 | 6 | C-dopa/L-dopa | 27 | N |
Note. SMMSE = Standardized Mini Mental State Examination; F = female; M = male; Y = yes; N = no.